Your browser doesn't support javascript.
loading
Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
Matta, María Gabriela; Pulido, Laura; Herrera-Paz, Juan José; Picco, José M; Wolff, Sebastian; Tse, Gary; Garcia-Zamora, Sebastian.
Afiliación
  • Matta MG; Pharmacology Department, School of Medicine, FASTA University, Mar del Plata, Argentina.
  • Pulido L; Department of Pulmonology, Sanatorio Americano, Rosario, Argentina.
  • Herrera-Paz JJ; Cardiology Department, FLENI, Buenos Aires, Argentina.
  • Picco JM; Wolff Cardiology and Sport Medicine Institute, Mendoza, Argentina.
  • Wolff S; Wolff Cardiology and Sport Medicine Institute, Mendoza, Argentina.
  • Tse G; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China; Epidemiology Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China
  • Garcia-Zamora S; Cardiology Department, Delta Clinic, Rosario, Argentina. Electronic address: szamora@sanatoriodelta.com.ar.
Vaccine ; 41(9): 1541-1544, 2023 02 24.
Article en En | MEDLINE | ID: mdl-36725429
Immunizations for influenza and pneumococcus are effective interventions in reducing morbidity and mortality. The objective of this study was to describe the vaccination rates in volunteers from three regions of Argentina during the COVID-19 pandemic. In 2020, 3853 adults were surveyed, 61.6 % were females, 45 % were aged between 40 and 60 and 18.6 % were > 60 years old. The commonest comorbidities were hypertension (12.9 %), dyslipidemia (8.5 %), and smokers or former smokers (9.2 %). The global influenza vaccination rate was 37.7 %, pneumococcal vaccination 24.7 %, and both 17.8 %. Multivariable regression showed that the vaccination rate increased with age and the presence of comorbidities. However, in the subgroup with indications for both vaccines, 71.7 % had the influenza vaccine, 59 % had the pneumococcal vaccine, and 28.3 % received neither. Our study suggests that influenza and pneumococcal vaccine percentages in high-risk patients in Argentina remain sub-optimal. Immunizations with proven reductions in morbimortality could have also been relegated during the COVID pandemic.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / COVID-19 Límite: Adult / Female / Humans / Male País/Región como asunto: America do sul / Argentina Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Argentina

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / COVID-19 Límite: Adult / Female / Humans / Male País/Región como asunto: America do sul / Argentina Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article País de afiliación: Argentina